Abstract
Two landmark studies demonstrate synergistic approaches to gastrointestinal cancer management. Lin et al identified activin A receptor type 1C polymorphisms (rs4556933/rs77886248) as esophageal squamous cell carcinoma risk modifiers in Chinese Han populations through a case-control study (1264 patients/1361 controls), revealing transforming growth factor-beta pathway-mediated susceptibility in older male smokers (P < 0.001). Concurrently, Luo et al established imaging-based differentiation of pancreatic cancer subtypes (pancreatic ductal adenocarcinoma vs neuroendocrine tumors) via retrospective analysis of 500 cases (area under the curve = 0.89), enabling earlier intervention. These findings underscore the transformative potential of combining genetic risk stratification with advanced imaging to guide precision screening and therapeutic strategies, addressing critical gaps in esophageal and pancreatic cancer outcomes.